Idexx Laboratories (IDXX)
NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$555.67-2.56%
Close 2026-07-08 · 1-day change
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→QuarterlyIQ Insights · IDXX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-07-07.
The screen ranks IDXX against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 50% of the time over the next year (vs 42% for the rest of the cohort, n=9129).
Over the trailing year it converted 1.10x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 49% of the time over the next year (vs 41% for the rest of the cohort, n=3127).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 48% for the rest of the cohort, n=4965).
Not investment advice. As of 2026-07-08.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.